CYT — Cyteir Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $111.95m
- -$17.29m
- 44
- 35
- 77
- 51
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 0.008 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Total Operating Expenses | 16.1 | 20.9 | 42.3 | 48.2 |
Operating Profit | -16.1 | -20.9 | -42.3 | -48.2 |
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -15 | -20.8 | -42.1 | -46.1 |
Net Income After Taxes | -15 | -20.8 | -42.1 | -46.1 |
Net Income Before Extraordinary Items | ||||
Net Income | -15 | -20.8 | -42.1 | -46.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -15 | -20.8 | -42.1 | -46.1 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.436 | -0.604 | -1.2 | -1.31 |
Dividends per Share |